Liquid Biopsy Market Size, Share, and Growth Forecast to 2034

According to Fortune Business Insights, the global liquid biopsy market size was valued at USD 11.66 billion in 2025. The market is projected to grow from USD 14.23 billion in 2026 to USD 106.49 billion by 2034, exhibiting a remarkable CAGR of 28.61% during the forecast period (2026–2034). The growing burden of cancer worldwide and increasing adoption of precision medicine are major factors driving the expansion of this market.

The global liquid biopsy market has experienced rapid growth in recent years due to increasing demand for non-invasive cancer diagnostics and advancements in molecular testing technologies. Liquid biopsy is an innovative diagnostic technique that detects cancer-related biomarkers such as circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and extracellular vesicles through blood or other bodily fluids. This method allows clinicians to identify cancer early, monitor tumor progression, and evaluate treatment effectiveness without the need for invasive tissue biopsies.

Information Source: https://www.fortunebusinessinsights.com/liquid-biopsy-market-102506 

Rising Demand for Non-Invasive Cancer Diagnostics

Liquid biopsy technology has gained widespread attention because it offers a safer and less invasive alternative to traditional tissue biopsies. Conventional biopsies often require surgical procedures, which can be painful and sometimes risky for patients. In contrast, liquid biopsy involves a simple blood test, making it easier for physicians to conduct frequent monitoring and disease tracking.

The growing prevalence of cancer worldwide is one of the key drivers for market growth. Early detection of cancer significantly improves treatment outcomes, and liquid biopsy plays an essential role in identifying genetic mutations and tumor markers at an early stage. In addition, the increasing use of personalized medicine has further accelerated demand for advanced diagnostic technologies that provide real-time insights into tumor genetics.

Another major factor contributing to market growth is the increasing investment in research and development by biotechnology and pharmaceutical companies. Continuous advancements in next-generation sequencing (NGS), polymerase chain reaction (PCR), and biomarker discovery technologies have enhanced the accuracy and efficiency of liquid biopsy tests.

Market Segmentation Insights

The liquid biopsy market is segmented based on product, application, end user, and region.

By product, the market is categorized into kits & reagents and instruments. The kits and reagents segment holds a significant share due to their extensive use in cancer diagnostics and biomarker detection. Continuous technological improvements in assay kits and reagents are also contributing to the expansion of this segment.

Based on application, the market is divided into oncology, non-invasive prenatal testing (NIPT), and others. Among these, the oncology segment dominates the market, as liquid biopsy is widely used for detecting and monitoring various cancers, including lung, breast, colorectal, and prostate cancer.

By end user, the market includes hospitals, clinical laboratories, and other healthcare institutions. Hospitals and clinical laboratories represent the largest end-user segment due to the increasing adoption of advanced diagnostic tools and the growing number of cancer patients requiring regular monitoring.

Regional Market Analysis

From a regional perspective, North America dominates the global liquid biopsy market, accounting for a major share in 2025. The region’s leadership can be attributed to strong healthcare infrastructure, early adoption of advanced diagnostic technologies, and the presence of major biotechnology companies.

The United States remains the largest contributor to the North American market, supported by increasing research activities and high healthcare spending. The availability of advanced genomic testing technologies and supportive regulatory frameworks further drives the market growth in this region.

Europe also holds a substantial share in the global market due to the rising prevalence of cancer and growing awareness regarding early disease detection. Countries such as Germany, the U.K., and France are investing heavily in precision medicine and diagnostic innovations.

Meanwhile, the Asia Pacific region is expected to witness the fastest growth during the forecast period. Rapid improvements in healthcare infrastructure, rising healthcare expenditures, and increasing awareness about early cancer detection are key factors driving the market in countries such as China, India, and Japan.

Key Companies in the Liquid Biopsy Market

The competitive landscape of the liquid biopsy market is characterized by the presence of several global biotechnology and diagnostics companies that are actively investing in research, product development, and strategic partnerships. Key players focus on expanding their product portfolios and strengthening their technological capabilities to gain a competitive advantage.

Major companies operating in the liquid biopsy market include:

• F. Hoffmann-La Roche Ltd.

• Illumina, Inc.

• Guardant Health, Inc.

• Thermo Fisher Scientific Inc.

• QIAGEN N.V.

• Bio-Rad Laboratories, Inc.

• Exact Sciences Corporation

• Myriad Genetics, Inc.

• Laboratory Corporation of America Holdings

• Natera, Inc.

Future Outlook

The liquid biopsy market is expected to grow significantly in the coming years due to technological advancements, increasing adoption of precision medicine, and the rising prevalence of cancer worldwide. The development of highly sensitive and cost-effective diagnostic tools will further accelerate the adoption of liquid biopsy tests across hospitals and clinical laboratories.